App-Quantinova.ai

Conditional inactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development

L Sheng - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Ergocalciferol

Waiting for Treatment: Addressing Inequities in access to essential medications for metastatic breast cancer

C Faucette - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Young women with early stage breast cancer and their supportive care needs: Results from a regional survey

J Ratcliffe - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A meta-analysis of cognitive impairment in breast cancer survivors treated with chemotherapy

LJ Bernstein - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cognitive dysfunction

N/A

A retrospective evaluation of cardiovascular recovery and oncologic outcomes associated with interrupted and continuous adjuvant trastuzumab in the setting of mild left ventricular dysfunction

JD Gibson - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Left ventricular dysfunction

Trastuzumab

Young women with breast cancer in Mexico: A report of the pilot phase of the Mujer Joven y Fuerte prospective cohort

CM Villareal-Garza - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Ozagrel

Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2 advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies

HS Rugo - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Evaluation of the effects of palbociclib (PAL) + letrozole (LET) on QTc

A Ruiz - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Palbociclib

Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2 advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

V Diéras - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Breast cancer

Fulvestrant

Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

NC Turner - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Capecitabine

A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

I Krop - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

A high specificity and sensitivity qPCR Assay for HER2, ER and PR gene expression in breast cancer patients

KD Rinker - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

First-line ribociclib + letrozole in patients with HR+, HER2 advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

HA Burris - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Secondary liver cancer

Ribociclib

Phyllodes tumours of the breast: The British Columbia cancer agency experience

MF Rodrigues - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Mofezolac

Prospective family cohort analyses of gene-environment interactions in breast cancer: Body mass index

MB Terry - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Capecitabine in early breast cancer: A meta-analysis of randomized controlled trials

A Natori - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cyclophosphamide

Population based long term outcomes of pathologic complete response after neoadjuvant chemotherapy in stage I-III breast cancer: The British Columbia experience

J Sun - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Leptin receptor (OB-R) in breast carcinoma tissue: Ubiquitous expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity

MC Chang - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Alora

Mechanism of drug resistance in relation to sites of metastases: Meta-analyses of randomized controlled trials in advanced breast cancer

S Niraula - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

N/A

Clinical utility of PgR with various cutpoints using 3 commercial assays relative to 15yr survival

EN Kornaga - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Tamoxifen

Filters

28841 Abstracts